Vaccines

Janssen on Wednesday announced it has stopped the phase 3 Mosaico trial because the investigational HIV vaccine regimen it was testing was not effective in preventing HIV infection compared with placebo.

Health officials on Wednesday declared an end to an Ebola outbreak in Uganda that killed 55 people and infected at least 142 in less than 4 months.

A single dose of the Jynneos mpox vaccine reduces hospitalization risk and disease severity, a study found, although researchers emphasized that people at risk for the disease should complete the two-dose vaccine series.

Updated COVID-19 shots, including bivalent boosters, dominated vaccine news in 2022, but good news also came for vaccines against malaria, Ebola and cancer.

There was plenty of FDA news this year not related to COVID-19.

Experts argued for the development of COVID-19 vaccines that can be delivered at the site of infection, but questioned whether it is possible to make a mucosal vaccine that prevents SARS-CoV-2 infection — and not just severe disease.

Two randomized, placebo-controlled trials of three Ebola vaccine regimens demonstrated that they are safe and spur lasting antibodies in both children and adults, according to findings reported in The New England Journal of Medicine.

The FDA has granted priority review to a biologics license application for Pfizer’s respiratory syncytial virus vaccine candidate, RSVpreF, for older adults, according to the company.

About 15% of parents have not discussed any vaccines with their child’s primary care provider during the COVID-19 pandemic, a recent national survey found.

Real-world data showed that bivalent messenger RNA vaccines against SARS-CoV-2 provided “significant additional protection” against symptomatic COVID-19 among people who had received two, three or four previous monovalent doses.